ISSN : 2146-3123
E-ISSN : 2146-3131

Crohn's Disease Associated Pyoderma Gangrenosum Treated with Adalimumab
Despoina Kakagia 1, Eleni Efremidou 2, Nikolaos Lyratzopoulos 2, Alexandros Mitrakas 2, Michael Pitiakoudis 2, George Kouklakis 3
1Democritus University in Thrace Medical School, Plastic, Reconstructive Surgery, Alexandroupolis, Greece
2Democritus University in Thrace Medical School, General Surgery, Alexandroupolis, Greece
3Democritus University in Thrace Medical School, Endoscopy, Alexandroupolis, Greece
DOI : 10.5174/tutfd.2010.04446.1
Pages : 93-95


Pyoderma gangrenosum is a known, though infrequent, ulcerative skin lesion that is often associated with systemic inflammatory and immunologic diseases. Objective: To present the efficacy of Adalimumab, a fully human Tumour Necrosis Factor-α antagonist, in the treatment of pyoderma gangrenosum associated with Crohn's disease. Methods: A young male patient with pyoderma gangrenosum of the shin as the first sign of clinically active Crohn's disease, who was treated with Adalimumab, is herein presented. Results: Almost complete healing of the lesion was achieved after 12 weeks of treatment. Conclusions: Successful treatment outcome suggests that Adalimumab is not only a therapeutic option for Crohn's disease but may also be a safe and effective therapy for Pyoderma gangrenosum associated with the disease. Pyoderma gangrenosum should be suspected in any cutaneous ulcerative lesion occurring in patients with Crohn's disease.

Keywords : Adalimumab, Crohn's disease, immunomodulating agents, pyoderma gangrenosum
Viewed : 2846
Downloaded : 1033